Company profile: Elutia
1.1 - Company Overview
Company description
- Provider of customized tissue products, including CanGaroo, an acellular envelope for securing implantable electronic devices to promote healthy tissue integration and wound healing; SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction with rapid integration and revascularization and a low inflammatory response; and CanGarooRM, a next-generation drug-eluting biomatrix for securing cardiac devices or neurostimulators.
Products and services
- CanGaroo: An implant-grade acellular envelope that secures pacemakers and defibrillators, promoting healthy tissue integration and wound healing while stabilizing implantable electronic devices within surrounding tissue
- CanGarooRM: A clinical-grade next-generation drug-eluting biomatrix intended to secure cardiac implantable electronic devices or implantable neurostimulators, coupling mechanical device stabilization with integrated drug-eluting properties
- SimpliDerm: A surgical-grade human acellular dermal matrix for soft tissue reconstruction, offering rapid integration and revascularization with a low inflammatory response in reconstructive procedures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elutia
Innocoll
HQ: United States
Website
- Description: Provider of targeted drug delivery solutions focused on biodegradable surgical implants and topically applied healthcare products, including XARACOLL, a resorbable collagen implant with bupivacaine for pain relief up to 24 hours after open inguinal hernia repair; POSIMIR, a single‑site bupivacaine injection providing relief up to 72 hours after arthroscopic subacromial decompression; the COLLARx collagen matrix platform; and CDMO services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innocoll company profile →
Mipharm
HQ: Italy
Website
- Description: Provider of pharmaceutical manufacturing across oral solids, oral liquids, nasal sprays, semi-solids, and suppositories; customized and secure packaging; research and development for new formulations and optimization of existing ones; clinical trial logistics; and formulation development and production of experimental drugs for clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mipharm company profile →
Enable Injections
HQ: United States
Website
- Description: Provider of on-body wearable drug delivery systems enabling patients to self-administer large amounts of medication. Products include the enFuse wearable delivery system with constant-pressure delivery and a progress gauge; Smart enFuse with Bluetooth connectivity for data transmission to a smartphone app; and syringe/vial transfer systems for mixing and transferring medication, including dual-vial and automatic reconstitution options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enable Injections company profile →
Softhale
HQ: Belgium
Website
- Description: Provider of soft mist inhalation (SMI) devices, including an innovative handheld non-thermal mechanical nebulizer, enabling effective respiratory delivery of pharmaceutical drugs to the lungs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Softhale company profile →
Bionaut Labs
HQ: United States
Website
- Description: Provider of microscale robotic technology for precise delivery of therapies to targeted CNS disease areas; a platform for biologics and small molecules; diagnostic fluid and tissue sampling; long-term in vivo sensing and monitoring; localized electrical stimulation or dampening; and minimally invasive hydrocephalus treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bionaut Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elutia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elutia
2.2 - Growth funds investing in similar companies to Elutia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elutia
4.2 - Public trading comparable groups for Elutia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →